Vitamin K2 Clinical Study

Asakura H, Myou S, Ontachi Y, Mizutani T, Kato M, Saito M, Morishita E, Yamazaki M, Nakao S.

Department of Internal Medicine (III), Kanazawa University School of Medicine, Japan. hasakura@med3.m.kanazawa-u.ac.jp

The administration of menaquinone-4 (MK-4), one of subclasses of vitamin K2, significantly reduces bone loss in postmenopausal osteoporotic women. However, concerns have been raised about whether vitamin K administration alters the hemostatic balance by inducing a thrombotic tendency. We investigated were whether the administration of vitamin K in the form of MK-4 induced a thrombotic tendency in 29 elderly patients with osteoporosis (5 men, 24 women; age range 78.7+/-5.1 years). Patients were administered 45 mg/day (three times a day, 30 min after each meal) of MK-4 for 12 weeks. Blood samples were obtained from the patients at 0, 4 and 12 weeks after the start of MK-4 administration. A number of hemostatic parameters remained stable under the markedly increased plasma levels of MK-4. However, in patients with suspected vitamin K deficiency, whose plasma levels of vitamin K or factor VII were low, vitamin-K-dependent clotting factors such as factor VII and prothrombin were gradually increased after administration of MK-4. No changes in the sensitive molecular markers such as TAT and F1+2, which reflect the amount of thrombin generated in the blood stream, were observed, even in those patients with suspected vitamin K deficiency. These results indicate that MK-4 can be administered safely, with regard to maintaining the hemostatic balance, to osteoporotic patients receiving no anticoagulant therapy.

PMID: 11846334 [PubMed - indexed for MEDLINE]

<< Back to Vitamin K2 Clinical Study List

We are strictly a bulk supplier to manufacturers – we do not sell to re-sellers or individuals. Our minimum order size is approximately 25 kilos. We are one of only a few suppliers that carry $5 million product liability insurance for our customers. AHD International LLC is classified as a importer, exporter, manufacturer, distributor of nutritional ingredients depending on the ingredient specified. AHD has 5 warehouse locations across North America and sales agents in over 10 countries. We are the only ingredient company to be awarded the Dun and Bradstreet's fastest growing company in America twice in 1999 and 2002.

For quotes please click here

*"These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."